Expert Interview
Discussing the use of Exelixis' cabozantinib to treat advanced neuroendocrine tumors
Ticker(s): EXELInstitution: Mayo Clinic
- Board certified in Internal medicine, Hematology, and Oncology
- Specializes in gastrointestinal (GI) malignancies and treats conditions such as: neuroendocrine tumors (NETs); neuroendocrine carcinoma (NEC); colon cancer; esophageal cancer; liver cancer; pancreatic cancer, and stomach cancer; and has co-authored papers and book chapters on these subjects.
- Clinical research interest and expertise in neuroendocrine tumors, for which he currently treats ~200 patients with NETS.
What are you currently using to treat neuroendocrine tumors?
Added By: wilson_adminHow do you think you will use cabozantinib in neuroendocrine tutors?
Added By: wilson_adminCan you walk us through how you use the agents (somatostatin analogs, lutetium, everolimus, imatinib, chemo) and what kind of results you're seeing?
Added By: catalin_adminDo you think Cabo might be more preferable to sunitinib, and are there any other targets in development for pNETs or extrapancreatic NETs that you're following?
What is the unmet need for pancreatic and extrapancreatic neuroendocrine tumors (NETs), and do you see potential for new therapeutic options in this space?
Added By: catalin_adminHow do patients tolerate treatment with TKIs such as cabozantinib, and what are the common side effects and management strategies for these treatments?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
